Delayed drug sensitivity [4];Sindrome de sensibilidad retardada a fármacos

Revista Clinica Espanola

Volumn 203, Issue 12, 2003, Pages 617-618

  del Valle Loarte, P ^a   Cervero Jimenez M ^a   Joya Seijo, M D ^a   Jusdado Ruiz Capillas, J J ^a   Torres Perea, R ^a  

^a HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; NEVIRAPINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ASPIRATION BIOPSY; CASE REPORT; CLINICAL FEATURE; DELAYED HYPERSENSITIVITY; DISEASE PREDISPOSITION; DRUG HYPERSENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LABORATORY TEST; LETTER; MALE; THORAX RADIOGRAPHY; CHEMICALLY INDUCED DISORDER; NOTE; SYNDROME;

ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; SYNDROME;

EID: 0345832174     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0014-2565(03)71376-9     Document Type: Letter

References (13)

1. Pérez Pimiento AJ, Calvo Manuel E, Lozano Tonkín C, Espinós Pérez D. Síndrome de sensibilidad retardada, a fármacos. Rev Clin Esp 2002;6:339-46.
2. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
3. Hewitt RG. Abacavir hipersensitivity reaction. CID 2002; 34: 1137-42.
4. Wassef M, Keiser P. Hypersensitivity to zidovudine: report of a case of anaphylaxis and review of the literature. Clin Infect Dis 1995;20:1387-9.
5. Herranz P, Fernández-Diaz ML, Lucas R, González Garcia J, Casado M. Cutaneous vasculitis associated with didanosine. Lancet 1994;344:680.
6. Tancrede-Bohin E, Range F, Bournerias I, Roujeau JC, Guillaume JC. Hypersensitivity syndrome associated with zalcitabine therapy. Lancet 1996;347:971.
7. Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immuno-deficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother 2000;44:794-7.
8. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998;27:1321-2.
9. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000;30:227-8.
10. Goodgame JC, Pottage JC Jr, Jablonowski H, Hardy WD, Stein A, Fischl M, et al. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Antivir Ther 2000;5:215-25.
11. Hernández J, Williams V, Sawyer R, et al. The rate of hypersensitivity reactions to abacavir is similar in underrepresented populations and incarcerated subjects [abstract 184]. En: Program and abstracts of the 5th International Congress on the Therapy of HIV Infection. Glasgow; 2000.
12. Thurmond LM, Thorborn D, Ravitch J, et al. Immunohistologic characterization of skin rash observed in patients on abacavir who experience a hypersensitivity reaction [abstract P51]. En: Program and abstracts of the 2nd International Work on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto; 2000.
13. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999;13:999-1000.